On the afternoon of June 10, the “First China Medical Device Industry Innovation and Development Session” (hereinafter referred to as the Session) themed on “Innovation in value and leapfrog development” was held in Guangzhou International Convention Center. The Session was one of the main parallel sessions of the “12th China Bioindustry Convention” (hereinafter referred to as the Convention). It was mainly sponsored by the China Association for Medical Devices Industry (CAMDI), and obtained substantial supports from the Committee of the Convention, Guangzhou Municipal Development and Reform Commission, Guangzhou Bio-Industry Alliance, etc. Nearly 200 participants from a great number of renowned and leading enterprises concerning biological medicine and medical devices at home and abroad actively attended this event, including Guangzhou Pharmaceutical Holdings Limited (GPHL), MGI Tech Co., Ltd. (MGI), Guangzhou Wondfo Biotech Co., Ltd. (Wondfo), Guangzhou Sun-Shing Biotech Co., Ltd. (Sun-Shing), Top Gene Tech (Guangzhou) Co., Ltd., Medprin Regenerative Medical Technologies Co., Ltd. and United Imaging Healthcare (Beijing).
In the Session, the following specialists delivered informative speeches: Pu Tun, deputy inspector of Guangzhou Administration for Market Regulation, Hu Huihui, government affairs officer of CAMDI, Wu Changhai, chairman of Committee of Chinese Traditional Medical Devices under CAMDI and executive deputy general manager of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Zeng Chenguang, chairman of Sun-Shing, Yan Miaoli, person responsible for the company qualification, MGI, Kang Keren, vice president of Wondfo, Zuo Panli, vice president of United Imaging Healthcare (Beijing).
A round table presentation themed on “opportunities and challenges under new policies” was conducted at the end of the Session. It seems like that the “best age” has come with the issuance and implementation of policies as well as the formation of favorable regulatory environment over the last two years. In particular, the establishment of review and approval channel and the marketing authorization holder system for innovative medical devices, and other benefits from policies entails the industry a promising future. Under the support of the affirmative policies, the whole industry has ushered in opportunities and challenges. Deep insights were shared by experts and entrepreneurs from various industries with respect to marketing authorization holder system, innovation of medical devices, the future development direction of the industry, etc.
It is the trend that to replace imported products with domestic ones in the future market of China. Meanwhile, China is providing more supports to domestic devices by releasing and implementing sound policies. The “Made in China” goods with high cost performance, sooner or later, will be a big threat to other well-known international products around the world. The Session ended on a successful note in the heated discussion.
